Attitudes of Dilated Cardiomyopathy Patients and Investigators Toward Genomic Study Enrollment, Consent Process, and Return of Genetic Results

Alisa D. Blazek1, Daniel D. Kinnamon1, Elizabeth Jordan1, Hanyu Ni1 and Ray E. Hershberger2,*

Precision medicine genetics study design requires large, diverse cohorts and thoughtful use of electronic technologies. Involving patients in research design may increase enrollment and engagement, thereby enabling a means to relevant patient outcomes in clinical practice. Few data, however, illustrate attitudes of patients with dilated cardiomyopathy (DCM) and their family members toward genetic study design. This study assessed attitudes of 16 enrolled patients and their family members (P/FM), and 18 investigators or researchers (I/R) of the ongoing DCM Precision Medicine Study during a conjoint patient and investigator meeting using structured, self-administered surveys examining direct-to-participant enrollment and web-based consent, return of genetic results, and other aspects of genetic study design. Survey respondents were half women and largely identified as white. Web-based consent was supported by 93% of P/FM and 88% of I/R. Most respondents believed that return of genetic results would motivate study enrollment, but also indicated a desire to opt out. Ideal study design preferences included a 1-hour visit per year, along with the ability to complete study aspects by telephone or web and possibility of prophylactic medication. This study supports partnership of patients and clinical researchers to inform research priorities and study design to attain the promise of precision medicine for DCM.

Enrollment and continued engagement of thousands of participants in genetics studies are ideal for precision medicine research. Large, family-based cohorts that include racially diverse and potentially environmentally exposed individuals may be necessary to comprehend complex genetic architecture. To ensure study success and ultimately improve the value of health research, there is a need for recruitment and enrollment motivation strategies.1 Researchers must then maintain enrollee engagement throughout the study.

We designed a qualitative pilot study to understand study participant preferences and inform design of large genetics research studies. We surveyed enrolled patients, their family members, and investigators of the ongoing Dilated Cardiomyopathy (DCM) Precision Medicine Study funded by the National Institutes of Health, a multisite consortium-based study that is determining whether idiopathic DCM has a genetic basis.2 Capitalizing on the unique opportunity afforded by a conjoint

1Division of Human Genetics, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA; 2Division of Human Genetics & Division of Cardiovascular Medicine, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA. *Correspondence: Ray E. Hershberger (ray.hershberger@osumc.edu)

Received: June 15, 2020; accepted: September 23, 2020. doi:10.1111/cts.12909
patient and investigator meeting, we anonymously queried participants about genetic study enrollment motivations, attitudes toward direct-to-participant consent processes, desirability of return of genetic results, and other aspects of study design. Our goal was to collect this information to facilitate design of future studies with a patient-centric focus.

Due to widespread adoption of direct-to-consumer genome sequencing, electronic results, and data platforms, and mobile health applications ("apps"),³ we aimed to determine desirability of direct-to-participant recruitment and consent, which places patients and research participants at the center of decision making and has been shown to facilitate study enrollment and retention.⁴ Return of electronic, complete genetic testing results were considered another key incentive to maintain study interest.⁵,⁶ However, no studies about patient attitudes toward DCM genetic studies have been performed, especially in the context of direct-to-participant enrollment and receipt of expanded genetic results.⁷ Furthermore, we wanted to understand patient preferences for length, format, and frequency of study visits, as well as acceptability of proactive treatment. We therefore conducted a pilot study to address these issues and to benefit researchers considering design of genetics studies.

METHODS
Parent study
This is a pilot study conducted for The DCM Precision Medicine Study, which aims to test the hypothesis that most DCMs of unknown cause, or idiopathic dilated cardiomyopathy, has mostly a genetic basis.² The study aims to determine if DCM, whether sporadic or familial, has mostly a genetic basis by using cardiovascular clinical and genetic information from 1,300 patients with DCM and their first-degree family members.²,⁸ Additionally, an intervention to help probands discuss genetics with their family is being tested in a randomized trial to determine if it will motivate family member clinical screening. The University of Pennsylvania single institutional review board approved the study, acting as a central institutional review board for all member sites of the consortium. All study participants provided informed consent.

Eligibility and recruitment
Pilot study participants included enrolled patients of the Precision Medicine Study and their first-degree family members (patients (P)/family members (FM)) as well as Precision Medicine Study investigators and other researchers (I/R) consisting of cardiologists, data scientists, clinical genetic counselors, and research administrators. The study recruited all attendees of the Spring Scientific Symposium of the DCM Consortium held at The Ohio State University April 25–26, 2019, a joint meeting of the DCM Research Project Consortium members (https://dcmproject.com/), and the DCM Foundation (https://dcmfoundation.org/), which aims to provide hope and support to those with DCM. The purpose of the meeting was to discuss the status of the Precision Medicine Study and to plan future studies. Conjoint sessions were intended to integrate insights and feedback of DCM Ps/FMs into the study planning process.

Survey development and administration
Structured surveys were developed to elicit attitudes and preferences toward study design, direct-to-participant recruitment and web-based consent, return of genetic results, communication of genetic risk, and medical interventions. For example, survey respondents were asked to consider if potential study participants would be able to successfully answer study eligibility questions by the web, the optimal time required for a web-based consent process, and the medium for providing support during consent, such as chat, telephone, or email with study personnel. Return of results questions assessed desirability of complete genomic information receipt as well as understanding of results and sharing preferences. Study design questions consisted of medication use and study visit procedures.

Surveys were developed before the Symposium by brainstorming. The brainstorming group, a cardiologist, two genetic counselors, a statistician/geneticist, and a molecular biologist, was asked to record independently as many survey items as possible in 10 minutes. Responses were shared aloud to refine questions. Similar ideas were collated around select themes. Final questions were reviewed by all group members for clarity and consistency with study intent. The 20-question surveys consisted of multiple choice, Likert scale (not likely, somewhat unlikely, neutral, somewhat likely, and likely), and Yes/No questions as well as free text short answer questions. I/R and P/FM questionnaires were identically structured, but the I/R version queried them regarding their patients’ beliefs. For example, researchers were asked how much time they think a participant would be willing to spend completing a web-based consent form.

Surveys were self-administered anonymously immediately after the conclusion of the Symposium. All attendees were invited to participate in the surveys; not all attendees took the survey, or answered all questions, thus the number of responses differed slightly for each question.

Data analyses
Due to the descriptive nature of this pilot study and small sample sizes, responses from P/FM and I/R were examined separately and not compared statistically. Responses from patients and their family members were grouped due to small sample sizes. Percentages of “Likely” or “Very likely” Likert scale questions were tabulated. Short answer written responses were examined for themes using a qualitative descriptive approach, and similar themes were grouped. Noted differences among responses also were reported. Data are available upon request from the corresponding author.

RESULTS
Symposium attendees and respondents
Demographic characteristics of the attendees are presented in Table 1. Seven distinct families were represented by the P/FM attendees. Attendees were nearly even split by sex, but the majority (76%) identified as white or Caucasian. Sixteen P/FM (53% of those attending) and 18 I/R (33%) completed the surveys.
Survey multiple choice responses

Most P/FM (93%) responded favorably to web-based recruitment and consent (Table 2) and were likely to return to the consent form to complete it after exiting (88%). Further, most (87%) believed they could assess their own eligibility for enrollment. The majority (81%) of respondents thought web-based consent form completion should require 30 minutes or less. Live chat, telephone call, or email assistance from study staff were similarly preferable.

The return of genetic results was seen as a motivating factor for research study participation (60%), but participants admittedly would not necessarily understand results without counseling (56% unable to understand). Participants would share results with their physician regardless of whether these results were negative or positive. In terms of study design, 69% of P/FM were willing to take a disease-preventative drug and 93% would be willing to return for ongoing study visits. P/FM preferred these visits to be 1 hour or less in length (59%) and occur yearly or less (88%), and would complete parts of the visit by telephone (40%) or by web (60%).

Like P/FM, most (88%) I/R believed that P/FM would respond favorably to web-based recruitment and consent (Table 2), but I/R were not convinced that participants would return to a web consent form after exiting (44% favorable responses) or that participants would answer eligibility questions accurately (56% favorable responses). The majority (89%) of I/R thought participants would be willing to spend 30 minutes or less completing a web-based consent form, and that assistance via phone or live chat would be preferred (76%).

I/R viewed receipt of complete genomic information motivating for study participation (74%), but doubted that participants could understand these results without counseling by medical professionals. I/R also believed that participants would share positive (94%), but not necessarily negative (28%), results with physicians. Researcher responses varied regarding the possibility of participants taking medicine to prevent a disease; however, I/R believed family members would take medication once diagnosed with early stages of disease, or if a family member was diagnosed with DCM or experienced a serious DCM-related outcome. Researchers were generally in agreement with P/FM in terms of study visit format (79% 1 hour or less long, 56% yearly or less, 65% by tele phone, and 78% by web).

Survey free text, short answer responses

P/FM short answer questions and responses are highlighted (Table 3). Representative themes in the responses were grouped and presented together, whereas unique viewpoints are also highlighted.

P/FM multiple choice responses indicated favorable views of complete genomic information receipt (60%), but written responses revealed misgivings. One participant did not want to know about other disease risks because she “has plenty to already think about,” especially if she was unable to reduce her risk. Another participant expressed concerns about data privacy. Actionable and accurate results were preferable. In terms of how they receive genetic testing information, patients welcomed more communication, especially via telephone. Further follow-up after the return of results by telephone call was desirable. One researcher commented, “I have seen some genetic blame being placed—your side, my side, etc.”

Researchers and participants agreed that motivation to enroll in genetics studies was due to concern for family members and altruism. One researcher commented: “Even though we all want to be altruistic, in reality we want to protect our kids. I think that’s really a big driver.” Conversely, one participant expressed frustration with participation in a study they would ultimately not directly benefit from (Table 3).

The most important aspect of treatment was interaction with and quality information from healthcare personnel. Likewise, the most beneficial aspect of participating in the DCM Precision Medicine Study was information, and P/FM expressed a need for DCM research information and communication. I/R agreed the DCM Precision Medicine Study had provided patient benefit, primarily through gained actionable knowledge of the familial nature of DCM as well as provision of hope, peace of mind, and engagement with the disease. I/R were admittedly unsure about what participants would want others to know about their disease. A few said participants would want others to know that it is genetic. One stated, “even though they look ok, it is a real disease,” similar to a patient response. No I/R respondents replied that the most important aspect of participant treatment was interaction with physicians. In fact, P/FM seek this interaction and as much disease-specific information as available.

For future studies, P/FM again wanted information and for their doctors to better understand genetic disease. I/R believed P/FM wanted to receive genetic testing results faster as well as information about advances in the field and new research findings, while dealing with less study-related paperwork, time commitment, and procedures.

The greatest impediment to study participation cited by both I/R and P/FM was logistics, including time and money spent, travel to study site, etc. Lack of symptoms also was a common response from P/FM. I/R responses included lack of motivation by unaffected family members, desire to receive a nongenetic cause, and lack of perceived direct benefit.

Either healthcare providers (cardiologist or genetic counselors) or family members communicated disease information to P/FM. Most of these individuals communicated the information in person, and the information was...
Table 2 Multiple choice survey questions and responses

| Patient/family member facing question | Patient/family member responses (n = 16) | Researcher responses (n = 16) |
|---------------------------------------|----------------------------------------|------------------------------|
| Web-based consent themed questions    |                                        |                              |
| 1. You are considering enrolling in a research study. If given the option of a web-based study consent form to be performed at your convenience as an alternative to scheduling an in-person, face-to-face consent appointment, how likely are you to opt to consent through a web-based form? Likert Scale Responses: 1—Unlikely, 2—Somewhat Unlikely, 3—Neutral, 4—Somewhat Likely, 5—Likely | 93% Likely or somewhat likely | 88% Likely or somewhat likely |
| 2. Suppose that you are unable to complete the web-based consent form at once. How likely are you to return to the online form to complete after saving your progress and exiting? Likert Scale Responses: 1—Unlikely, 2—Somewhat Unlikely, 3—Neutral, 4—Somewhat Likely, 5—Likely | 88% Likely or somewhat likely | 44% Likely or somewhat likely |
| 3. How confident are you in your ability to accurately answer questions about your eligibility for the DCM Research Project by answering a series of questions about your cardiovascular health history? Likert Scale Responses: 1—Not Confident, 2—Somewhat Non Confident, 3—Neutral, 4—Somewhat Confident, 5—Confident | 87% Likely or somewhat confident | 56% Likely or somewhat confident |
| 4. How much time would you be willing to spend completing a web-based consent form? Less than 10 minutes, 10–20 minutes, 20–30 minutes, 30–60 minutes, over an hour | 81% Preferred 30 minutes or less | 89% Responded 30 minutes or less |
| 5. If you would like to ask a member of the study staff a question about content of the web-based consent form, which type of communication would you prefer in order to reach a member of the study staff to address your question: Live Chat, Telephone Call, Email, Other [Specify] (U.S. mail, Online, Text) | 29% Live chat, 35% telephone call, 29% email | 36% Live chat, 40% telephone call, 22% email |
| Return of genetic results themed questions |                                        |                              |
| 6. Would you more likely to participate in a research study if you could receive your complete genomic information? Likert Scale Responses: 1—Unlikely, 2—Somewhat Unlikely, 3—Neutral, 4—Somewhat Likely, 5—Likely | 60% Likely or somewhat likely | 74% Likely or somewhat likely |
| 7. Do you think you would be able to understand your results by yourself without further counseling? Likert Scale Responses: 1—Unlikely, 2—Somewhat Unlikely, 3—Neutral, 4—Somewhat Likely, 5—Likely | 56% Likely or somewhat unlikely | 89% Likely or somewhat unlikely |
| 8. Do you think you would be able to understand your results without further counseling by a Clinical Genetic Counselor? Likert Scale Responses: 1—Unlikely, 2—Somewhat Unlikely, 3—Neutral, 4—Somewhat Likely, 5—Likely | 56% Likely or somewhat unlikely | 83% Likely or somewhat unlikely |
| 9. Do you think you would be able to understand your results without further counseling by an MD? Likert Scale Responses: 1—Unlikely, 2—Somewhat Unlikely, 3—Neutral, 4—Somewhat Likely, 5—Likely | 31% Likely or somewhat unlikely | 33% Likely or somewhat unlikely |
| 10. Would you discuss your positive results with your physician/s? Likert Scale Responses: 1—Unlikely, 2—Somewhat Unlikely, 3—Neutral, 4—Somewhat Likely, 5— Likely | 88% Likely or somewhat likely | 94% Likely or somewhat likely |
| 11. Would you discuss your negative results with your physician/s? Likert Scale Responses: 1—Unlikely, 2—Somewhat Unlikely, 3—Neutral, 4—Somewhat Likely, 5—Likely | 94% Likely or somewhat likely | 28% Likely or somewhat likely |
| Study design themed questions          |                                        |                              |
| 12. How likely are you to take a medication to prevent a disease you don’t yet have? Likert Scale Responses: 1—Unlikely, 2—Somewhat Unlikely, 3—Neutral, 4—Somewhat Likely, 5—Likely | 69% Likely or somewhat likely | 53% Likely or somewhat likely |
| 13. Do you think that family members would rather have early signs of a disease (e.g., DCM) rather than some very early findings that will lead to DCM (but that do not meet a “disease” classification) to start a medication? Likert Scale Responses: 1—Unlikely, 2—Somewhat Unlikely, 3—Neutral, 4—Somewhat Likely, 5—Likely | 56% Likely or somewhat likely | 100% Likely or somewhat likely |
| 14. Do you think that it is only after a family member has DCM that the family will be proactive in this regard? Likert Scale Responses: 1—Unlikely, 2—Somewhat Unlikely, 3—Neutral, 4—Somewhat Likely, 5—Likely | 87% Likely or somewhat likely | 94% Likely or somewhat likely |
| 15. Do you think that it is only after a family member has DCM and some bad outcome (e.g., sudden death, advanced heart failure, heart transplant, death), that they would seriously consider taking a medication with very early findings? Likert Scale Responses: 1—Unlikely, 2—Somewhat Unlikely, 3—Neutral, 4—Somewhat Likely, 5—Likely | 71% Likely or somewhat likely | 84% Likely or somewhat likely |
| 16. Would you be willing to return for ongoing visits for study-related testing (e.g., possibly to include heart checks, medical testing, surveys, and other data collection)? Yes/No | Yes 98% | Yes 94% |

(Continues)
most often shared immediately after receiving a diagnosis. At least one proband acknowledged difficulty with explaining the ambiguity of DCM to family members and getting them to participate. Another factor affecting communication was fear and anxiety surrounding the uncertain potential for disease.

Providers could best support P/FM by understanding the genetic basis of diseases. In terms of their own needs, providers want more information in the form of point of care resources to help with genetic information, support for clinical care post diagnosis, lay summaries of evolving research, and best therapies and preventative measures. They also want greater access to genetic counselors.

Similar to the multiple-choice responses for this question, P/FM responded positively to a web-based consent process, but wanted the capability to contact a representative with questions. I/R questioned patient self-assessment accuracy. All expressed concern about generational adoption of the technology. One researcher asked, “What about the absence of a conversation? It’s very cold, right?”

I/R correctly predicted that P/FM want to understand complete risks, benefits, and side effects before agreeing to start a drug to reduce DCM risk. P/FM nearly unanimously would be willing to try non-drug interventions, such as exercise, diet, and enhanced screening, but I/R predicted low adherence to these lifestyle modifications. One asymptomatic FM had already been prescribed a low dose ACE inhibitor. Another FM of childbearing age was not sure she would take a preventive drug. One researcher commented, “There is a cost to everything we do. Taking a pill every day is a psychological reminder to someone that they could have a major heart problem; may cause psychological harm to someone. Evidence of preclinical disease is still disease.” Another said, “The thing is, we haven’t proven this concept. It’s not evidence-based is the problem. We are trying to create that evidence base. There is nothing benign about any medication we give.”

**DISCUSSION**

A scientific symposium comprised of participants from the DCM Precision Medicine Study provided an ideal opportunity for pilot data collection regarding attitudes toward aspects of large DCM genomic research studies. This project is unique in that both patients and researchers were queried to construct a thematic analysis intended to inform future, patient-centered genetics studies. Our study suggested that patient feedback may inform a study design that can attract and retain enrollees as well as benefit patient outcomes. Consideration of enrollment and retention strategies for large studies is crucial. Our findings are consistent with recent studies that engaged research participants in the design or conduct of research to enhance relevance to patients.9–14

We used a conjoint meeting to elicit study design details, where topics relevant to all participants of the DCM Precision Medicine Study were explored in a shared setting. Prior studies also have demonstrated impact of and rationale for patient and researcher involvement in research meetings.15,16 In our particular study, collected survey responses from our meeting were examined for three key themes regarding genetic research design that constituted the major outcome measures of our analysis.

**Web-based consent**

Given the popularity of web-based, direct-to-consumer genetic testing,17 we believed that providing potential study participants with an option to consent at their convenience via the web would motivate study participation. Web-based consent is increasingly accepted in all types of studies.18 Our data supported this finding, although we clarified that provision of technical support and awareness of generational preferences was desirable. Web-based consent for genetics studies could be successful if: (i) the survey ideally requires 30 minutes or less to complete; (ii) technical support is readily available; and (iii) the web interface can accommodate varying skillsets.

**Return of results**

Receipt of complete genetic results was not universally desired or a motivating factor for enrollment. Instead of being viewed as a benefit of study enrollment and consistent with previous studies, P/FM expressed anxiety over receipt of genetic results and the potential for revealing new genetic risks unrelated to their primary diagnosis.19 Considerations such as limitations of direct-to-consumer genetic testing, accuracy of results, potential for loss of patient confidentiality, etc. increased the anxiety.

Conversely, when P/FM receive results pertinent to their diagnosis, they prefer as much information as possible to
Table 3 Free text short answer survey questions and responses

| Question                                                                                     | Selected responses from patients and their family members |
|--------------------------------------------------------------------------------------------|----------------------------------------------------------|
| Q1: How do you think you would feel about receiving more information (than just DCM related genetic information) when genetic testing results are returned to you? | “I want a doctor to share all information with me, even if it is messy.” “The way I work is the more information the better, but I noticed in my session that not everyone’s like that. There’s a lot of fear out there. Not everyone wants to know everything I want to know.” “I want to be able to pick what information I want to receive.” “I would like if there were an option to only find out about defined, treatable diseases.” “I have done ancestry.com and that was fine, but I have enough on my plate with the diagnosis. It wouldn’t be motivating to me.” “It seems like it’s fine to provide it, but I don’t know that it would necessarily motivate me more to join the study. I’m feeling motivated for my husband who has DCM and my children already.” “I love 23andMe and so do my friends. What’s cool about the Corel [sic] study is that it’s been seven years and I’m still getting genetic results. As the research continues to develop, they will continue providing information. The opportunity is available on the website to see or not see my result.” |
| Q2: What motivated you/would motivate you to enroll in a study returning genetic information? | “My family is affected. We don’t know what’s going on genetically, but we’re happy to contribute to research and get answers.” “I have a hard time agreeing to do the study—I already have the disease and don’t have children. What are the other benefits? Why should I participate? I so appreciate what you guys do, but it didn’t change anything. My treatment is still the same, my condition is still the same; it didn’t change my daily life.” |
| Q3: What aspects of your treatment have been most important to you? Has the study been beneficial to you? Why or why not? What do you want other people to know about your disease or situation? | The most important aspect of treatment was interaction with and quality information from healthcare personnel. The most beneficial aspect of participating in the DCM Precision Medicine Study was information. |
| Q4: What would you like to see more of/less of in future genetic studies? | “Dissemination of information. Doctors have all this knowledge and we aren’t getting that.” “General cardiologists need to be on board with this. Honestly, my husband was diagnosed with a heart condition at age 50. I never heard about a genetic connection until a few years ago, when we had dinner with (a cardiologist involved with the study). She asked if he had been tested and the kids could be tested. And so, no cardiologist has ever mentioned it. They are the ones who could say, it would be really interesting for you to go and get involved in this study.” |
| Q5: What do you think is the greatest impediment to family member participation in a DCM genetic study? | “Not everyone wants to know their genetic information, especially when they have no symptoms.” “Sometimes the physicians are reluctant to screen a family member if they have no symptoms.” “My brother has six kids and a defibrillator. It’s been a lot of years since my son was transplanted, so a lot of years since anyone was acute. The younger kids, my brother’s kids, don’t see the need to get further screening. I think they think we’re healthy, what’s the big deal. They don’t see the imminent risk.” “A confusing process discourages people.” “It didn’t do a thing for me. I don’t have any change in my care, daily routine.” |
| Q6: What was your/your family’s experience with communicating risk? Who communicated it/relationship to you? How was it shared? (telephone, email, etc.)? What was stated? When was it shared (immediately after finding out; after letter received; or much later...after personal processing of info or after another event occurred in family)? | “I was the driver. I was able to get nine people in my family tested. I convinced them via calling, face to face. Logistics of it is difficult, and that may be why 80% of the resistance is encountered—the echo, ECG, blood draw, expense.” “Some family members may see affected relatives as anxious or worried. Why would other family members want to go through that voluntarily?” “There is a fear of insurance being adversely affected if a pre-existing condition is identified.” “We just said, we don’t want to scare you because we don’t know because my husband hadn’t been tested yet. They said, we wouldn’t have wanted to know because what would we do?” |
| Q7: What do providers need to conduct and support participants and families with genetic DCM? | “My PCP had told me there was no need to be tested for DCM, she was completely unaware of the genetic link.” “General cardiologists need more information to direct their patients.” “Providers need to understand the genetic basis of disease.” |
| Q8: You are considering enrolling in a research study. If given the option of a web-based study consent form to be performed at your convenience as an alternative to scheduling an in-person, face-to-face consent appointment, how likely are you to opt to consent through a web-based form? | “It could be helpful for reluctant or out-of-town family members.” “I would prefer it, even if it was long. I would rather do it that way than face-to-face.” “I would prefer it. The medical community is still stuck in the 1970s.” “One of the difficulties of in person consent is that it is going to take me an hour of my time. Whereas if I was on a web-based thing I could do it for five minutes and then come back to it. It is going to be a hassle either way but if you can reduce the time and hassle—you’re still going to have to look at some blood tests—but still for me one of the drawbacks is to drive somewhere and spend an hour doing all this stuff.” “I think one of the advantages of this approach is to enroll patients from sites distant from any coordinating site. … and distant from any genetic counselor so where are they going to have their blood drawn? There may not be any genetic counselor or someone associated with the study to complete the process.” “I would like that a lot. I just retired and I did every form possible online because I didn’t have time to talk to individual people or wait on the phone. I know my kids that are in their late 30s and early 40s have even less time than I have to spend on the phone. They don’t even like talking on the phone. They are very literate with the web.” “Level of comfort with technology goes down after about age 55 in the current population. Depends on ease of use and platform.” “I’m okay with it, but if I get stuck, I want to call somebody on the phone. I don’t want to have this chat. For me, as an older person, I’m okay starting on the web, but I want a phone number so I can talk to somebody.” |

(Continues)
include the latest disease research and detailed follow-up with genetic counselors and physicians. Patients preferred to receive life-threatening results through a personal meeting or telephone call, perhaps because the professional could explain the results and assist the patient with coping. Future studies might consider the use of web-based result return only when returning routine results without health implications. Options for receipt of complete or only selected genetic testing results may be preferable, as is consistent with previous research. Indeed, the American College of Medical Genetics’ current guidelines recommend the option to opt out of receipt of complete genome analysis. Consistent with our study, the most important patient-reported aspects of results return included receipt of no cost, actionable information, especially for serious diseases for which treatments exist, and availability of detailed written information to explain the results.

Study design preferences

P/FM and I/R shared similar views regarding study participation motivation, prophylactic drug use, and other aspects of study design. Motivation for enrollment in our family-based genetic studies was largely due to concern for children and other family members, as is consistent with participation in medical research studies in general. Some participants also mentioned altruism as a motivator. Researchers should take note of the emphasis on concern for family and use that information to increase study enrollment, motivation, and participation. Other motivators for study participation include some form of personal gain and improving knowledge and medical advancement.

P/FM noted that increased physician awareness of the genetic basis of diseases would improve P/FM support and conduct of future studies. Importantly, I/R often correctly predicted and agreed with the responses of P/FM, showing in particular that physicians recognize patient need for information as well as their desire to provide that information. I/R recognized their limitations with regard to understanding the genetic basis of diseases and expressed a need for more genetic counselor support. These results are consistent with patient perception that clinician genetic knowledge is poor and their desire for providers to be knowledgeable and work closely with genetics experts to provide the most informed care. This study showed that I/R did not fully understand the importance of their own interactions with patients. Providers should place importance on their ability to provide as much disease-specific genetic knowledge to their patients as possible.

There are several limitations of this study that could be addressed in future research. First, sample sizes were small, as this project was intended to be a qualitative pilot study. Second, the race/ethnicity of our P/FM sample was homogeneous. A more diverse population is recommended for true generalizability of these results. In addition, because survey data were collected at the conclusion of the meeting, it is possible that presentations and personal interactions may have influenced P/FM and I/R opinions on these thematic areas. Finally, the attitudes of enrolled participants may differ from those not enrolled. As a result, the opinions may not be directly generalizable to general DCM study participant populations.

CONCLUSIONS

Three major themes were investigated in this study. Web-based consent was viewed favorably, which coincides with increased implementation of direct-to-consumer technologies in research. Return of complete genetic testing results could be motivating to patient enrollment as long as only actionable results are delivered by an engaged, knowledgeable healthcare team. Patient and provider partnership when designing studies may help researchers and clinicians more fully realize the potential of precision medicine.

Acknowledgments. We thank the participants of this study, including the DCM families, without whom this effort would not be possible, and the DCM Consortium investigators of the DCM Precision Medicine Study (https://dcmproject.com/). We also acknowledge the DCM Foundation for collaboration in this event (https://dcmfoundation.org/). We recognize the valuable contribution of Ana Morales for contributing to study questionnaire development.

Funding. Research reported in this publication was supported by a parent award from the National Heart, Lung, and Blood Institute of the National Institutes of Health under Award Number R01HL128857 (Dr. Hershberger), which included a supplement from the National Human Genome Research Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Conflict of Interest. The authors declared no conflicts of interest for this work.

Author Contributions. A.D.B., D.D.K., E.J., H.N., and R.E.H. wrote the manuscript. A.D.B., D.D.K., E.J., H.N., and R.E.H. designed the research. A.D.B., D.D.K., E.J., H.N., and R.E.H. performed the research. A.D.B. analyzed the data.
1. Domecq, J.P. et al. Patient engagement in research: a systematic review. *BMC Health Serv. Res.* **14**, 69 (2014).
2. Kinnaman, D.D. et al. Toward genetics-driven early intervention in dilated cardiomyopathy: design and implementation of the DCM precision medicine study. *Circ. Cardiovasc. Genet.* **10**, e001826 (2017).
3. Kamarou, D. Regulating medical apps: which ones and how much? *BMJ* **347**, i6009 (2013).
4. Kaye, J. et al. From patients to partners: participant-centric initiatives in biomedical research. *Nat. Rev. Genet.* **13**, 371–376 (2012).
5. Williams, J.L. et al. Impact of a patient-facing enhanced genomic results report to improve understanding, engagement, and communication. *J. Genet. Couns.* **27**, 358–369 (2018).
6. Pilemer, F. et al. Direct release of test results to patients increases patient engagement and utilization of care. *PLoS One* **11**, e0154743 (2016).
7. National Academies of Sciences, Engineering, and Medicine. Applying an implementation science approach to genomic medicine: workshop summary. *Roundtable on Translating Genomic-Based Research for Health. (National Academies Press)* (Washington, DC, 2016).
8. Morales, A. et al. Variant interpretation for dilated cardiomyopathy (DCM): refinement of the ACMG/ClinGen guidelines for the DCM precision medicine study. *Circ. Genom. Precis. Med.* **13**, e002480 (2020).
9. Goodman, D. et al. Consent issues in genetic research: views of research participants. *Public Health Genom.* **19**, 220–228 (2016).
10. Freeman, B.D. et al. Surrogate receptivity to participation in critical illness genetic research: aligning research oversight and stakeholder concerns. *Chest* **147**, 979–988 (2015).
11. Freeman, B.D. et al. Considerations in the construction of an instrument to assess attitudes regarding critical illness gene variation research. *J. Empir. Res. Hum. Res. Ethics* **7**, 58–70 (2012).
12. Trinidad, S.B. et al. Genomic research and wide data sharing: views of prospective participants. *Genet. Med.* **12**, 486–495 (2010).
13. Trinidad, S.B. et al. Research ethics. Research practice and participant preferences: the growing gulf. *Science** **331**, 287–288 (2011).
14. Elberse, J.E., Pittens, C.A., de Cock Buning, T. & Broerse, J.E. Patient involvement in a scientific advisory process: setting the research agenda for medical products. *Health Policy** **107**, 231–242 (2012).
15. de Wit, M., Abma, T., Koelwijm-van Loon, M., Collins, S. & Kirwan, J. Involving patient research partners has a significant impact on outcomes research: a responsive evaluation of the international OMERACT conferences. *BMJ Open* **3**, e002241 (2013).
16. Elberse, J.E., Caron-Flinterman, J.F. & Broerse, J.E. Patient-expert partnerships in research: how to stimulate inclusion of patient expertise. *Health Expect.* **14**, 225–239 (2011).
17. Wysocki, K. & Osier, N. Direct to consumer versus clinical genetic testing. *J. Am. Assoc. Nurse Pract.* **31**, 152–155 (2019).
18. Yoo, B.K. et al. Cost-effectiveness of school-located influenza vaccination programs for elementary and secondary school children. *BMC Health Serv. Res.* **19**, 407 (2019).
19. Murphy Bollinger, J., Bridges, J.F., Mohamed, A. & Kaufman, D. Public preferences for the return of research results in genetic research: a conjoint analysis. *Genet. Med.* **16**, 932–939 (2014).
20. Sundby, A. et al. The preferences of potential stakeholders in psychiatric genomic research regarding consent procedures and information delivery. *Eur. Psychiatr.* **55**, 29–35 (2019).
21. Biesecker, B.B. et al. Web platform vs in-person genetic counselor for return of carrier results from exome sequencing: a randomized clinical trial. *JAMA Intern. Med.* **178**, 338–346 (2018).
22. Murphy, J. et al. Public expectations for return of results from large-cohort genetic research. *Am. J. Bioeth.* **8**, 36–43 (2008).
23. Richards, M.P., Ponder, M., Pharoah, P., Everest, S. & Mackay, J. Issues of consent and feedback in a genetic epidemiological study of women with breast cancer. *J. Med. Ethics* **29**, 93–96 (2003).
24. Tabor, H.K. et al. Informed consent for whole genome sequencing: a qualitative analysis of participant expectations and perceptions of risks, benefits, and harms. *Am. J. Med. Genet. A.* **158A**, 1310–1319 (2012).
25. Middleton, A. et al. Attitudes of nearly 7000 health professionals, genomic researchers and publics toward the return of incidental results from sequencing research. *Eur. J. Hum. Genet.* **24**, 21–29 (2016).
26. American College of Medical Genetics and Genomics. ACMG updates recommendations on “Opt Out” for genome sequencing return of results. *ACMG News.* <https://www.prnewswire.com/news-releases/acmg-updates-recommendation-on-opt-out-for-genome-sequencing-return-of-results-253369641.html> (2014).
27. Hoeyer, K., Olofsson, B.O., Mjøndal, T. & Lynøe, N. Informed consent and biobanks: a population-based study of attitudes towards tissue donation for genetic research. *Scand. J. Public Health* **32**, 224–229 (2004).
28. Dixon-Woods, M. et al. Beyond “misunderstanding”: written information and decisions about taking part in a genetic epidemiology study. *Soc. Sci. Med.* **65**, 2212–2222 (2007).
29. Baason, F., Futter, M.J. & Greenberg, J. Qualitative research methodology in the exploration of patients’ perceptions of participating in a genetic research program. *Ophthalmic Genet.* **28**, 143–149 (2007).
30. Kaphingst, K.A., Janoff, J.M., Harris, L.N. & Emmons, K.M. Views of female breast cancer patients who donated biologic samples regarding storage and use of samples for genetic research. *Clin. Genet.* **69**, 393–398 (2006).
31. Kost, R.G., Lee, L.M., Yessis, J., Coller, B.S. & Henderson, D.K. Assessing research participants’ perceptions of their clinical research experiences. *Clin. Transl. Sci.* **4**, 403–413 (2011).
32. Moutel, G. et al. Communication of pharmacogenetic research results to HIV-infected treated patients: standpoints of professionals and patients. *Eur. J. Hum. Genet.* **13**, 1055–1062 (2005).

© 2020 The Authors. *Clinical and Translational Science* published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.